Finance

Lists
Why is ACET down 2.11%?
Dive Deeper
ACET:NASDAQ
Adicet Bio Inc
$6.50
-2.11%
(-0.14) 1D
$6.56
+0.92% (+0.060)
After hours
Closed: Oct 2, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ACET...
Open
$6.70
High
$6.82
Low
$6.50
Mkt. cap
60.85M
Avg. vol.
243.32K
Volume
164.70K
52-wk high
$17.44
52-wk low
$6.01
EPS
-$13.02
Beta
1.62
Shares outstanding
9.36M
No. of employees
102
Open
$6.70
High
$6.82
Low
$6.50
Mkt. cap
60.85M
Avg. vol.
243.32K
Volume
164.70K
52-wk high
$17.44
52-wk low
$6.01
EPS
-$13.02
Beta
1.62
Shares outstanding
9.36M
No. of employees
102
News stories
From web sources and news partners
About Adicet Bio Inc
CEO-
Employees102
Founded2014
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websiteadicetbio.com
Analyst ratings
Based on 4 analysts giving stock ratings to ACET in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for ACET in the last 3 months.
Highest
Current $6.50
$34.00 (+423.08%)
Average
$25.00 (+284.62%)
Lowest
$18.00 (+176.92%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Driscoll
Wedbush
Buy
Reiterated
$28.00
+330.8%
09/29/2026
John Newman
Canaccord Genuity
Buy
Maintained
$18.00
+176.9%
09/29/2026
Boris Peaker
JonesTrading
Buy
Maintained
$20.00
+207.7%
09/28/2026
Robert Burns
H.C. Wainwright
Buy
Reiterated
$34.00
+423.1%
09/29/2026
Unknown Analyst
Wedbush
Buy
Reiterated
$25.00
+284.6%
08/06/2026
Anthea Li
Jefferies
Buy
Initiated
$19.00
+192.3%
05/04/2026
Soumit Roy
JonesTrading
Buy
Maintained
$20.00
+207.7%
04/06/2026
Asthika Goonewardene
Truist Financial
Buy
Reiterated
-
-
03/16/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$100.00
+1,438.5%
03/13/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
22.85M
25.04M
17.49M
18.45M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.10M
6.85M
4.08M
3.85M
Operating expense
27.95M
31.89M
21.57M
22.30M
Total operating expenses
27.95M
31.89M
21.57M
22.30M
Operating income
-27.95M
-31.89M
-21.57M
-22.30M
Other non operating income
-64.00K
-130.00K
7.00K
-60.00K
EBT including unusual items
-26.86M
-30.52M
-20.24M
-21.22M
EBT excluding unusual items
-26.86M
-30.52M
-20.24M
-21.22M
Income tax expense
-
-
-
143.00K
Effective tax rate
-
-
-
-0.67%
Other operating expenses
-
-
-
-
Net income
-26.86M
-30.52M
-20.24M
-21.36M
Net profit margin
-
-
-
-
Earnings per share
-4.64
-2.94
-1.88
-1.99
Interest and investment income
1.17M
1.52M
1.34M
1.17M
Interest expense
-12.00K
-24.00K
-23.00K
-22.00K
Net interest expenses
1.16M
1.50M
1.32M
1.15M
Depreciation and amortization charges
-
-
-
-
EBITDA
-26.38M
-30.41M
-20.23M
-21.10M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps